KR20120051603A - 항카드헤린 항체 - Google Patents

항카드헤린 항체 Download PDF

Info

Publication number
KR20120051603A
KR20120051603A KR1020117028845A KR20117028845A KR20120051603A KR 20120051603 A KR20120051603 A KR 20120051603A KR 1020117028845 A KR1020117028845 A KR 1020117028845A KR 20117028845 A KR20117028845 A KR 20117028845A KR 20120051603 A KR20120051603 A KR 20120051603A
Authority
KR
South Korea
Prior art keywords
antibody
asp
leu
val
thr
Prior art date
Application number
KR1020117028845A
Other languages
English (en)
Korean (ko)
Inventor
히로유키 아브라타니
리린 쟝
케이스케 이시이
카스시 코우다
아야 사카모토
케이코 카스미
히로시 오니시
요코 카유카와
Original Assignee
고쿠리츠다이가쿠호징 도쿄다이가쿠
가부시키가이샤 페르세우스 프로테오믹스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠다이가쿠호징 도쿄다이가쿠, 가부시키가이샤 페르세우스 프로테오믹스 filed Critical 고쿠리츠다이가쿠호징 도쿄다이가쿠
Publication of KR20120051603A publication Critical patent/KR20120051603A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020117028845A 2009-05-01 2010-04-30 항카드헤린 항체 KR20120051603A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009111834 2009-05-01
JPJP-P-2009-111834 2009-05-01
JPJP-P-2010-018416 2010-01-29
JP2010018416 2010-01-29

Publications (1)

Publication Number Publication Date
KR20120051603A true KR20120051603A (ko) 2012-05-22

Family

ID=43032279

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117028845A KR20120051603A (ko) 2009-05-01 2010-04-30 항카드헤린 항체

Country Status (8)

Country Link
US (3) US8455249B2 (de)
EP (1) EP2426149A4 (de)
JP (1) JP5723270B2 (de)
KR (1) KR20120051603A (de)
CN (1) CN102753579A (de)
AU (1) AU2010242338B2 (de)
CA (1) CA2760642A1 (de)
WO (1) WO2010126137A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711394A1 (en) * 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
JP5380553B2 (ja) 2010-02-10 2014-01-08 富士フイルムＲｉファーマ株式会社 放射性金属標識抗カドヘリン抗体
JP6243737B2 (ja) * 2010-10-27 2017-12-06 ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク Ｅ−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法
EP3708586A1 (de) * 2010-10-29 2020-09-16 Perseus Proteomics Inc. Anti-cdh3-antikörper mit hoher internalisierungskapazität
JPWO2012176765A1 (ja) * 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
US20150037354A1 (en) * 2012-03-15 2015-02-05 The Resesrch Foundation for The State University of New York Combination therapies including inhibitors of the extracellular domain of e-cadherin
SG11201506358PA (en) * 2013-02-15 2015-09-29 Perseus Proteomics Inc Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
JP2017520575A (ja) 2014-07-01 2017-07-27 ファイザー・インク 二重特異的ヘテロ二量体ダイアボディおよびその使用
AU2015347015B2 (en) 2014-11-14 2019-02-14 Novartis Ag Antibody drug conjugates
HUE061730T2 (hu) * 2015-04-17 2023-08-28 Amgen Res Munich Gmbh Bispecifikus antitest-konstrukciók CDH3-hoz és CD3-hoz
CA2991799A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286647A (en) 1982-05-21 1994-02-15 University Of California Human-human hybridomas for neoplasms
US4618577A (en) 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
CA1247538A (en) 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
EP0754225A4 (de) 1993-04-26 2001-01-31 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
AU6973094A (en) 1993-06-24 1995-01-17 Leiras Oy Composition for ophthalmic use
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US6048972A (en) 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
WO2002097395A2 (en) 2001-05-31 2002-12-05 Chiron Corporation P-cadherin as a target for anti-cancer therapy
US20040247555A1 (en) * 2002-10-15 2004-12-09 Eli Sprecher Methods of and compositions for modulating hair growth via P-cadherin modulators
AU2003304203A1 (en) * 2002-10-29 2005-01-04 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
EP1871808A2 (de) 2005-03-31 2008-01-02 Xencor, Inc. Fc-varianten mit verbesserten eigenschaften
CN101432303A (zh) * 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗cdh3抗体的效应物功能来损伤细胞的方法
WO2008121160A2 (en) 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
EA201001603A1 (ru) * 2008-04-04 2011-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитела против кадгерина, блокирующие рост опухоли, ангиогенез и метастазирование

Also Published As

Publication number Publication date
AU2010242338A1 (en) 2011-12-01
WO2010126137A1 (ja) 2010-11-04
US8455249B2 (en) 2013-06-04
EP2426149A1 (de) 2012-03-07
AU2010242338B2 (en) 2013-12-19
US9017683B2 (en) 2015-04-28
CN102753579A (zh) 2012-10-24
CA2760642A1 (en) 2010-11-04
EP2426149A4 (de) 2013-01-23
JPWO2010126137A1 (ja) 2012-11-01
US20120136140A1 (en) 2012-05-31
US20130245232A1 (en) 2013-09-19
US20130243771A1 (en) 2013-09-19
JP5723270B2 (ja) 2015-05-27

Similar Documents

Publication Publication Date Title
KR20120051603A (ko) 항카드헤린 항체
EP3191517B1 (de) Kreuzreaktive siglec-antikörper
SA518390904B1 (ar) مستقبلات مولد مضاد خيمرية تقوم على أجسام مضادة أحادية الحقل وطرق لاستخدامها
CN112566698A (zh) T细胞受体和表达该t细胞受体的工程化细胞
KR20210013165A (ko) GUCY2c에 특이적인 항체 및 이의 용도
CN117586401A (zh) 抗pd-1抗体及其用途
CN114560941B (zh) Cldn18.2的抗体及其应用
US9127061B2 (en) Anti-human P-cadherin (CDH3) recombinant antibody
US20140234342A1 (en) Nkp46-mediated nk cell tuning
CN110914304A (zh) Cd96抗体、其抗原结合片段及医药用途
TR201808018T4 (tr) Anti-B7-H3 antikoru.
CN114206929B (zh) 一种抗tigit免疫抑制剂及应用
EP3323831A1 (de) Monoklonaler anti-aggrus-antikörper, domäne in aggrus, die für die bindung an clec-2 erforderlich ist, und verfahren zum screening auf aggrus-clec-2-bindungsinhibitor
CN110790839A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
US20240050473A1 (en) Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
CN113527489A (zh) 抗cd73的抗体及其用途
EP2905335A1 (de) Antikörper gegen menschliches dlk-1 mit in-vivo-antitumorwirkung
CN112812179B (zh) 高亲和力高特异性抗cmtm6单克隆抗体及其用途
EP3656794A1 (de) Zusammensetzungen und verfahren zur detektion von krebs
CA3226996A1 (en) Antibodies for treating cancer
CN113831411A (zh) 针对l1cam的单域抗体及其衍生蛋白和应用
US20200024347A1 (en) Or10h1 antigen binding proteins and uses thereof
EP4261228A1 (de) Spezifisch an das strepto-tag ii-tag bindender antikörper und verwendung davon
CN111704668B (zh) 抗ccr4抗体及其在治疗癌症中的应用
CN117025541A (zh) 一种靶向b7-h3并共表达细胞因子和趋化因子的car-t细胞及其用途

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid